Last updated on October 2018

Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial


Brief description of study

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to evaluate safety of immune tolerance induction (ITI) treatment with turoctocog alfa (a recombinant factor VIII) in patients who have developed neutralising antibodies against factor VIII after exposure to subcutaneous turoctocog alfa pegol during participation in NN7170-4213 (NCT02994407)

Clinical Study Identifier: NCT03588741

Contact Investigators or Research Sites near you

Start Over

Novo Nordisk

Novo Nordisk Investigational Site
Belgrade, Serbia
3.74miles
  Connect »